ES2605946T3 - Imidazopiridazinas sustituidas - Google Patents
Imidazopiridazinas sustituidas Download PDFInfo
- Publication number
- ES2605946T3 ES2605946T3 ES13710986.4T ES13710986T ES2605946T3 ES 2605946 T3 ES2605946 T3 ES 2605946T3 ES 13710986 T ES13710986 T ES 13710986T ES 2605946 T3 ES2605946 T3 ES 2605946T3
- Authority
- ES
- Spain
- Prior art keywords
- alkyl
- group
- halo
- alkoxy
- represent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Un compuesto de fórmula general I:**Fórmula** en la que: A representa**Fórmula** en la que * indica el punto de unión de dicho grupo con el resto de la molécula; R2 representa un grupo metilo, etilo o ciclopropilo; en el que dicho grupo metilo o etilo está opcionalmente sustituido, en forma idéntica o diferente, con 1, 2, 3 o 4 grupos seleccionados entre: halógeno, -OH, -CN, alcoxi C1-C3-; en el que dicho grupo ciclopropilo está opcionalmente sustituido, en forma idéntica o diferente, con 1, 2, 3 o 4 grupos seleccionados entre: halógeno, -OH, -CN, alquil C1-C3-, alcoxi C1-C3-, HO-alquil C1-C3-, halo-alquil C1-C3-; R3 representa -C (R3a)(R3b)(R3c); R3a, R3b representan, independientemente cada uno del otro, un átomo de hidrógeno o un átomo de halógeno o un grupo hidroxi, alquil C1-C3-, HO-alquil C1-C3-, alquenil C2-C4-, halo-alquil C1-C3-, alcoxi C1-C3- o halo-alcoxi C1-C3-, con la condición de que R3a y R3b no representan ambos un átomo de hidrógeno y R3a y R3b no representan ambos un grupo hidroxi; o R3a, R3b juntos representan >=O o >=C(R3d)(R3e); o R3a, R3b junto con el átomo de carbono al que se unen, forman un anillo ciclopropilo o ciclobutilo; en el que dicho anillo ciclopropilo o ciclobutilo está opcionalmente sustituido, en forma idéntica o diferente, con 1 o 2 grupos R3d; o R3 representa**Fórmula** en la que * indica el punto de unión de dicho grupo con el resto de la molécula; R3c representa un grupo fenilo; en el que dicho grupo fenilo está sustituido, en forma idéntica o diferente, con 1, 2, 3 o 4 grupos R7; R3d, R3e representan, en forma independiente entre sí, un átomo de hidrógeno o un grupo alquil C1-C3-; R4 representa un átomo de hidrógeno, un átomo de halógeno, o un grupo -CN, alquil C1-C3-, alcoxi C1-C3-, halo-alquil C1-C3- o halo-alcoxi C1-C3-; R5 representa un grupo alquil C1-C6-, -(CH2)m-(heterocicloalquilo de 3 a 7 miembros), alcoxi C1-C6-alquil C1-C6- o halo-alquil C1-C6- ; en el que dicho grupo -(CH2)m-(heterocicloalquilo de 3 a 7 miembros) está opcionalmente sustituido, en forma idéntica o diferente, con 1, 2 o 3 grupos R8 ; R6, R6a, R6b representan, independientemente cada uno del otro, un átomo de hidrógeno o un grupo alquil C1-C6-; R7 representa un átomo de halógeno, o un grupo hidroxi-, -CN, alcoxi C1-C6-, alquil C1-C6-, halo-alquil C1-C6-, R6a(R6b)Nalquil C1-C6-, HO-alquil C1-C6-, alcoxi C1-C6-alquil C1-C6-, halo-alcoxi C1-C6-alquil C1-C6-; R8 representa un átomo de halógeno, o un grupo -CN, hidroxi-, alquil C1-C6-, halo-alquil C1-C6-, HO-alquil C1-C6-, alcoxi C1-C6- o halo-alcoxi C1-C6-; m es un número entero de 0, 1 o 2 ; n es un número entero de 0, 1 o 2 ; o un estereoisómero, un tautómero, un N-óxido, un hidrato, un solvato o una sal farmacéuticamente aceptable del mismo o una mezcla de los mismos.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12159455 | 2012-03-14 | ||
EP12159455 | 2012-03-14 | ||
EP13154139 | 2013-02-06 | ||
EP13154139 | 2013-02-06 | ||
PCT/EP2013/054841 WO2013135612A1 (en) | 2012-03-14 | 2013-03-11 | Substituted imidazopyridazines |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2605946T3 true ES2605946T3 (es) | 2017-03-17 |
Family
ID=47913379
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES13710986.4T Active ES2605946T3 (es) | 2012-03-14 | 2013-03-11 | Imidazopiridazinas sustituidas |
Country Status (10)
Country | Link |
---|---|
US (1) | US9512126B2 (es) |
EP (1) | EP2825540B1 (es) |
JP (1) | JP6166289B2 (es) |
CN (1) | CN104284896B (es) |
AR (1) | AR090323A1 (es) |
CA (1) | CA2867061A1 (es) |
ES (1) | ES2605946T3 (es) |
HK (1) | HK1206022A1 (es) |
UY (1) | UY34677A (es) |
WO (1) | WO2013135612A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9512126B2 (en) | 2012-03-14 | 2016-12-06 | Bayer Intellectual Property Gmbh | Substituted imidazopyridazines |
MX2015017119A (es) | 2013-06-11 | 2016-04-06 | Bayer Pharma AG | Derivados de prodroga de triazolpiridinas sustituidas. |
MA38657A1 (fr) * | 2013-06-13 | 2018-05-31 | Bayer Pharma AG | Combinaison d'un dérivé d'imidazopyridazine et d'un agent mitotique pour le traitement du cancer |
EP3283642B1 (en) | 2015-04-17 | 2023-10-11 | Netherlands Translational Research Center Holding B.V. | Prognostic biomarkers for ttk inhibitor chemotherapy |
IL288541B (en) | 2015-07-07 | 2022-08-01 | Janssen Vaccines Prevention B V | vaccine against rsv |
GB201907616D0 (en) * | 2019-05-29 | 2019-07-10 | Galapagos Nv | Novel compounds and pharmaceutical compositons thereof for the treatment of diseases |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
HUP9903965A3 (en) | 1996-08-28 | 2002-02-28 | Pfizer | Substituted 6,5-hetero-bicyclic derivatives |
DK0991628T3 (da) | 1997-05-28 | 2005-05-17 | Aventis Pharma Inc | Quinolin- og quinoxalinforbindelser, der inhiberer blodpladeafledt vækstfaktor og/eller p561ck-tyrosin-kinaser |
US6514989B1 (en) | 2001-07-20 | 2003-02-04 | Hoffmann-La Roche Inc. | Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives |
JP2004346016A (ja) | 2003-05-22 | 2004-12-09 | Otsuka Chemical Co Ltd | トリフルオロメチルキノキサリン化合物、その製造方法、及び有害生物防除剤 |
WO2005030121A2 (en) | 2003-06-30 | 2005-04-07 | Hif Bio, Inc. | Compounds, compositions and methods |
EP1799680A2 (en) | 2004-10-07 | 2007-06-27 | Warner-Lambert Company LLC | Triazolopyridine derivatives as antibacterial agents |
US20070049591A1 (en) | 2005-08-25 | 2007-03-01 | Kalypsys, Inc. | Inhibitors of MAPK/Erk Kinase |
US7723336B2 (en) | 2005-09-22 | 2010-05-25 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
US20070078136A1 (en) | 2005-09-22 | 2007-04-05 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
WO2007065010A2 (en) | 2005-12-02 | 2007-06-07 | Hif Bio, Inc. | Anti-angiogenesis compounds |
KR20090026288A (ko) | 2006-05-31 | 2009-03-12 | 갈라파고스 엔.브이. | 퇴행성 및 염증성 질환의 치료에 유용한 트리아졸로피라진 화합물 |
AU2007284562B2 (en) | 2006-08-16 | 2013-05-02 | Exelixis, Inc. | Using PI3K and MEK modulators in treatments of cancer |
CN103641829A (zh) | 2006-08-30 | 2014-03-19 | 塞尔佐姆有限公司 | 作为激酶抑制剂的三唑衍生物 |
WO2008133192A1 (ja) * | 2007-04-19 | 2008-11-06 | Takeda Pharmaceutical Company Limited | 縮合イミダゾール化合物およびその用途 |
US7592342B2 (en) | 2007-05-10 | 2009-09-22 | Smithkline Beecham Corporation | Quinoxaline derivatives as PI3 kinase inhibitors |
KR20100049073A (ko) | 2007-07-18 | 2010-05-11 | 노파르티스 아게 | 비시클릭 헤테로아릴 화합물 및 키나제 억제제로서의 그의 용도 |
JP2010535804A (ja) | 2007-08-09 | 2010-11-25 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | Pi3キナーゼ阻害薬としてのキノキサリン誘導体 |
MX2010002115A (es) | 2007-08-23 | 2010-06-01 | Aztrazeneca Ab | 2-anilinopurin-8-onas como inhibidores de ttk/mps1 para el tratamiento de trastornos .proliferativos. |
US8263595B2 (en) | 2007-08-31 | 2012-09-11 | Merck Serono Sa | Triazolopyridine compounds and their use as ask inhibitors |
GB0719803D0 (en) | 2007-10-10 | 2007-11-21 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
CA2706578A1 (en) | 2007-11-27 | 2009-06-04 | Cellzome Limited | Amino triazoles as pi3k inhibitors |
WO2009155121A2 (en) | 2008-05-30 | 2009-12-23 | Amgen Inc. | Inhibitors of pi3 kinase |
TWI491610B (zh) | 2008-10-09 | 2015-07-11 | 必治妥美雅史谷比公司 | 作為激酶抑制劑之咪唑并嗒腈 |
WO2010092015A1 (en) | 2009-02-10 | 2010-08-19 | Cellzome Limited | Urea triazololo [1, 5-a] pyridine derivatives as pi3k inhibitors |
NZ594508A (en) | 2009-02-13 | 2013-12-20 | Fovea Pharmaceuticals | [1, 2, 4] triazolo [1, 5 -a] pyridines as kinase inhibitors |
US8729082B2 (en) | 2009-04-29 | 2014-05-20 | Bayer Intellectual Property Gmbh | Substituted imidazoquinoxalines |
TW201107329A (en) * | 2009-07-30 | 2011-03-01 | Oncotherapy Science Inc | Fused imidazole derivative having ttk inhibitory action |
EP2473498A1 (en) | 2009-09-04 | 2012-07-11 | Bayer Pharma Aktiengesellschaft | Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors |
EP2343294A1 (en) | 2009-11-30 | 2011-07-13 | Bayer Schering Pharma AG | Substituted triazolopyridines |
EP2343295A1 (en) | 2009-11-30 | 2011-07-13 | Bayer Schering Pharma AG | Triazolopyridine derivates |
EP2343297A1 (en) | 2009-11-30 | 2011-07-13 | Bayer Schering Pharma AG | Triazolopyridines |
JP5824464B2 (ja) | 2010-01-15 | 2015-11-25 | ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド | γセクレターゼ調節物質としての新規置換トリアゾール誘導体 |
US20110190269A1 (en) | 2010-02-01 | 2011-08-04 | Karlheinz Baumann | Gamma secretase modulators |
CA2801031A1 (en) | 2010-06-01 | 2011-12-08 | Bayer Intellectual Property Gmbh | Substituted imidazopyrazines |
TWI541243B (zh) | 2010-09-10 | 2016-07-11 | 拜耳知識產權公司 | 經取代咪唑并嗒 |
ES2556458T3 (es) | 2010-12-17 | 2016-01-18 | Bayer Intellectual Property Gmbh | 6-Imidazopirazinas sustituidas para uso como inhibidores de Mps-1 y TKK en el tratamiento de trastornos hiperproliferativos |
ES2530802T3 (es) | 2010-12-17 | 2015-03-06 | Bayer Ip Gmbh | Imidazopirazinas 6-tiosustituidas para uso como inhibidores de MPS-1 y TKK en el tratamiento de trastornos hiperproliferativos |
HUE025496T2 (en) | 2011-04-21 | 2016-04-28 | Bayer Ip Gmbh | Triazolopyridine derivatives |
EP2734205B1 (en) * | 2011-07-21 | 2018-03-21 | Tolero Pharmaceuticals, Inc. | Heterocyclic protein kinase inhibitors |
US9512126B2 (en) | 2012-03-14 | 2016-12-06 | Bayer Intellectual Property Gmbh | Substituted imidazopyridazines |
-
2013
- 2013-03-11 US US14/384,828 patent/US9512126B2/en not_active Expired - Fee Related
- 2013-03-11 JP JP2014561391A patent/JP6166289B2/ja not_active Expired - Fee Related
- 2013-03-11 EP EP13710986.4A patent/EP2825540B1/en not_active Not-in-force
- 2013-03-11 CA CA 2867061 patent/CA2867061A1/en not_active Abandoned
- 2013-03-11 ES ES13710986.4T patent/ES2605946T3/es active Active
- 2013-03-11 CN CN201380024787.9A patent/CN104284896B/zh not_active Expired - Fee Related
- 2013-03-11 WO PCT/EP2013/054841 patent/WO2013135612A1/en active Application Filing
- 2013-03-13 AR ARP130100808 patent/AR090323A1/es unknown
- 2013-03-14 UY UY0001034677A patent/UY34677A/es not_active Application Discontinuation
-
2015
- 2015-07-13 HK HK15106637.9A patent/HK1206022A1/zh not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
EP2825540A1 (en) | 2015-01-21 |
AR090323A1 (es) | 2014-11-05 |
US9512126B2 (en) | 2016-12-06 |
JP2015513559A (ja) | 2015-05-14 |
CA2867061A1 (en) | 2013-09-19 |
US20150104526A1 (en) | 2015-04-16 |
WO2013135612A1 (en) | 2013-09-19 |
JP6166289B2 (ja) | 2017-07-19 |
UY34677A (es) | 2013-10-31 |
HK1206022A1 (zh) | 2015-12-31 |
EP2825540B1 (en) | 2016-09-14 |
CN104284896B (zh) | 2016-06-01 |
CN104284896A (zh) | 2015-01-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2605946T3 (es) | Imidazopiridazinas sustituidas | |
CR20170118A (es) | Derivados espirodiamina como inhibidores de la aldosterona sintasa | |
AR105845A1 (es) | Compuestos de heteroarilo bicíclicos fusionados como moduladores de la función irak4 | |
AR089143A1 (es) | Triazolopiridinas sustituidas con actividad inhibidora de ttk | |
AR091193A1 (es) | HETEROCICLOS DE 5 MIEMBROS QUE CONTIENEN NITROGENO SUSTITUIDO POR CARBOXAMIDA O SULFONAMIDA COMO MODULADORES PARA EL RECEPTOR NUCLEAR HUERFANO RORg | |
ES2770058T3 (es) | Compuestos y composiciones destinados a modular las actividades de quinasa de EGFR mutante | |
AR101189A1 (es) | Heterociclos nitrogenados antiproliferativos y sus métodos de uso | |
CL2016002348A1 (es) | Agonistas del receptor muscarínico | |
PE20180483A1 (es) | Oxiesteroles y metodos de uso de los mismos | |
EA201791873A1 (ru) | Полиморф ингибиторов syk | |
MX2016011992A (es) | Derivados de piperidina-diona. | |
AR103833A1 (es) | Compuestos bicíclicos de sulfonamida cetona | |
MA40171A (fr) | Dérivés d'azamophinan et leur utilisation | |
AR094300A1 (es) | Derivados de quinolonas | |
AR085327A1 (es) | Inhibidores del virus de la hepatitis c | |
MA39956A (fr) | Analogues du benzomorphane et leur utilisation | |
CU20170007A7 (es) | Compuestos de imidazopiridazina | |
AR094762A1 (es) | Compuestos de hexahidropirano[3,4-d][1,3]tiazin-2-amina sustituida con heteroarilo | |
PE20160885A1 (es) | Derivados de purina 2,6 sustituidos en el tratamiento de transtornos proliferativos | |
PE20160201A1 (es) | Bencil-1h-pirazol[3,4-b]piridinas y su uso | |
CL2019000662A1 (es) | Inhibidores de dopamina–b–hidroxilasa. | |
AR111494A1 (es) | Compuestos de anilinoquinazolina c₅ y su uso en el tratamiento del cáncer | |
AR099047A1 (es) | Derivados etinilo | |
AR095040A1 (es) | Antagonistas de h3 que contienen un núcleo estructural de fenoxipiperidina | |
MX2017011978A (es) | Analogos deuterados de etifoxina, sus derivados y usos de estos. |